Reactive oxygen species damaged human serum albumin in patients with hepatocellular carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 3, 2007, Pages 395-404

  Rasheed, Zafar ^a,b   Ahmad, R ^b   Rasheed, N ^c   Ali, R ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b Sardar Bhagwan Singh Post Gratudate Institute of Biomedical Sciences & Research   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Hepatocellular carcinoma; HSA; Reactive oxygen; ROS HSA

Indexed keywords

HUMAN SERUM ALBUMIN; HYDROXYL RADICAL; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHOBICITY; LIPID OXIDATION; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN PURIFICATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; REACTIVE OXYGEN SPECIES; SERUM ALBUMIN;

EID: 35348895896     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ames B.N., Shigenaga M.K., Hagen T.M.: Oxidants, antioxidants and the degeneration diseases of aging. Proc. Natl. Acad. Sci. (U.S.A.) 90: 7915-7922, 1993.
2. Ashok B.T., Ali R.: Binding of human anti-DNA autoantibodies to reactive oxygen species modified DNA and probing oxidative DNA damage in cancer using monoclonal antibody. Int. J. Cancer 78: 404-409, 1998.
3. Shacter E.: Quantification and significance of protein oxidation in biological samples. Drug Met. Rev. 32: 307-326, 2000.
4. Poon H.F., Vaishnav RA., Gelchell T.V., Getchell, M.L., Butterfield D.A.: Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. Neurobiol. Aging 27: 1010-1019, 2006.
5. Tabner BJ., Turnbull S., El-Agnaf O., Allsop D.: Production of reaction oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative disease. Curr. Top. Med. Chem. 1: 507-517, 2001.
6. Yilmaz I.A., Akcay T., Cakatay, U., Telci, A., Ataus, S., Yalcin, V.: Relation between bladder cancer and protein oxidation. Int. Urol. Nepharol. 35: 345-350, 2003.
7. Stefaniak T., Krajewski J., Kobiela, J., Makarewicz W., Stanek A., Asano M., Kondo R., Wakabayasdi T., Gruca Z., Wozniak M.: Protein oxidation in male Syrian hamster kidney during estrogen-induced carcinogenesis. Pathophysiology 8: 269-273, 2002.
8. Arutyunova E.I., Danshina P.V., Domnina L.V., Pleten A.P., Muronetz V.I.: Oxidation of glyceraldehydes-3-phosphate dehydrogenase enhances its binding to nucleic acids. Biochem. Biophys. Res. Commu. 307: 547-552, 2003.
9. Shacter E., Williams J.A., Levine R.L.: Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Rad. Biol. Med. 18: 815-821, 1995.
10. Chou C.: Binding of rheumatoid and lupus synovial fluids and sera-derived human IgG rheumatoid factor to degalactosylated IgG. Arch. Med. Res. 33: 541-544, 2002.
11. Imai H., Nakano Y., Kiyosawa K., Tan E.M.: Increasing titres and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocelluar carcinoma. Cancer 71: 26-35, 1993.
12. Beacker J.C., Winkler, B., Klingen S., Brocker E.B.: Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73: 1621-1924, 1994.
13. Imai H., Ochs R.L., Kiyosawa K., Furuta S., Nakamura R.M., Tan E.M.: Nucleolar antigens and autoantibodies in hepatocelluar carcinoma and other malignancies. Amer. J. Pathol. 140: 859-870, 1992.
14. Malins D.C., Johnson P.M., Barker E.A., Polissar N.L., Wheelar T.M., Anderson K.M.: Cancer-related changes in the prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc. Natl. Acad. Sci. (U.S.A.) 100: 5401-5406, 2003.
15. Tamura N., Suou T., Hirayama C.: Anti-albumin antibodies in sera of patients with liver disease. Gastroenterol Jpn. 17: 469-475, 1982.
16. Peters T. Jr.: In, All About Albumin; Biochemistry, Genetics, and Medical Applications, Diego, S., ed. California : Academic Press, 127-277, 1996.
17. Cotran R.S., Kumar V., Robbins S.L.: In, Robbins pathologic basis of disease, 4th ed. Saunders, W.B., ed. Philadelphia: 925-937, 1989.
18. Eilat D., Fischel R., Zlotnick A.: Albumin-immunoglobulin complexes in human serum: classification and immunochemi3cal analysis. Scand. J. Immunol. 14: 77-88, 1981.
19. Jentoft J.E., Bolinger L., Ainslie G.R., Tandler B.: Forms of a self associating autoantibody complex between a monoclonal human IgG 1 and human serum albumin. Mol. Immunol. 24: 163-169, 1987.
20. Carballal S., Radi R., Kirk M.C., Barnes S., Freeman B.A., Alvarez B.: Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry. 42: 9906-9914, 2003.
21. Anraku M., Yamasaki K., Maruyama T., Kragh-Hansen U., Otagiri M.: Effect of oxidative stress on the structure and function of human serum albumin. Pharm. Res. 18: 632-639, 2001.
22. Rasheed, Z., Khan, M.W.A., Ali, R.: Hydroxyl radical modification of human serum albumin generated cross reactive antibodies. Autoimmunity 39: 479-488, 2006.
23. Oettl K., Hallstrom S., Jurcens G., Fuchs D., Blomster H., Schmut O., Sudi K., Greilberger J.: Reduced and oxidized forms of human serum albumin in sports, aging and disease. FEBS J. 271: H3-030P, 2005.
24. Suzuki E., Yasuda K., Takeda N., Sakata S., Era S., Kuwata K., Sogami M., Miura K.: Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res. Clin. Pract. 18: 153-158, 1992.
25. Era, S., Kuwata K., Imai H., Nakamura K., Hayaski T., Sogami M.: Age-related change in redox state of human serum albumin. Biochim. Biophys. Acta. 1247: 12-16, 1995.
26. Soejima A., Matsuzawa N., Hayashi T., Kimura R., Ootsuka T., Fukuoka K., Yamada A., Nagasawa T., Era S.: Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif. 22: 525-529, 2004.
27. Rigamonti C., Mottaran E., Reale E., Rolla R., Cipriani V., Capelli F., Boldarini R., Vidali M., Sartori M., Albano E.: Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 38: 42-49, 2003.
28. Jain S.K., Pemberton P.W., Smit A., McMohan R.F., Burrows P.C., Aboutwerat A., Warnes T.W.: Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J. Hepatology 36: 805-811, 2002.
29. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J.: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
30. Bradford M.M.: A rapid and sensitive method for the quantitation microgram quantity of protein utilizing the principle of protein dye binding. Anal. Biochem. 72: 248-254, 1976.
31. Wallevik K.: Reversible denaturation of human serum albumin by pH, temperature and guanidine hydrochloride. J. Biol. Chem. 245: 2650-2655, 1973.
32. Ali R., Alam K.: Evaluation of antibodies against free radical modified DNA by ELISA. In, Oxidative stress biomarkers and antioxidants protocols. Armstrong, D. ed. New Jersey: Humana Press, 171-181, 2002.
33. Habib S., Moinuddin, Ali R.: Acquired antigenicity of DNA after modification with peroxynitrite. Int. J. Biol. Macromol. 35: 221-225, 2005.
34. Dixit K., Ali R.: Role of nitric oxide modified DNA in the etiopathogenesis of systemic lupus erythematosus. Lupus 3: 95-100, 2004.
35. Tayyab S., Qasim M.A.: Purification and properties of buffalo serum albumin. Biochem. Int. 20: 405-415, 1990.
36. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Stadman E.R.: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186: 464-478, 1990.
37. Chen Y.H., Yang J.T., Martinez H.: Determination of the secondary structure of proteins by circular dichroism and optical rotatory dispersion. Biochemistry 11: 4120-4131, 1972.
38. Stryer L.: The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescence probe of non-polar binding sites. J. Mol. Biol. 13: 482-495, 1965.
39. Ahsan H., Ali A., Ali R.: Oxygen free radicals and systemic autoimmunity. Clin. Exp. Immunol. 131: 398-404, 2003.
40. Fabisiak J.P., Sedlov A., Kagan V.E.: Quantification of oxidative/nitrosative modification of CYS (34) in human serum albumin using a fluorescence-based SDS-PAGE assay. Antioxid. Redox Signal 4: 855-865, 2002.
41. Hayakawa A., Kuwata K., Era S., Sogami M., Shimanaka H., Yamamoto M., Dohi S., Hirose H.: Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J. Chromatogr. [B] 698: 27-33, 1997.
42. Cerutti P., Ghosh R., Oga Y., Amstad P.: The role of cellular defence in oxidant carcinogenesis. Environ. Health Perspect. 102: 123-129, 1994.
43. Himmelfarb J., Mcmonagle E.: Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int. 60: 358-363, 2001.
44. Dalle-Dome I., Rossi R., Giustarini D., Milzani A., Colombo R.: Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 29: 23-38, 2003.
45. Levine R.L., Williams J., Stadtman E.R., Shacter E.: Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233: 346-357, 1994.
46. Halliwell B., Gutteridge J.M.: The antioxidants of human extracellular fluids. Arch. Biochem. Biophys. 280: 1-8, 1990.